DELFRANA
LIVE

Serial Number

79404385

Owner

Novartis AG

Attorney

Maury M. Tepper, III

Filing Date

Jul 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DELFRANA Trademark

Serial Number: 79404385 • Registration: 8190680

DELFRANA is a trademark filed by Novartis AG on July 9, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Novartis AG (12 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

July 9, 2024

Registration Date

March 31, 2026

Published for Opposition

February 10, 2026

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma.

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 31, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2026 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 26, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 11, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 11, 2026 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 9, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 29, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 12, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 12, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 12, 2025 RFCR
NON-FINAL ACTION WRITTEN
Aug 11, 2025 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jan 19, 2025 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 22, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 21, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 21, 2024 DOCK
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 11, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 11, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 11, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 11, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 11, 2024 COAR
APPLICATION FILING RECEIPT MAILED
Oct 7, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 7, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 19, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 12, 2024 REPR